NRBO
NASDAQNeuroBo Pharmaceuticals Inc.
Latest news
25 items- INSIDERCEO & President Kim Hyung Heon covered exercise/tax liability with 2,867 shares, decreasing direct ownership by 4% to 63,799 units (SEC Form 4)4 - MetaVia Inc. (0001638287) (Issuer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - MetaVia Inc. (0001638287) (Filer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals Announces Strategic Realignment Ahead of Important Clinical Milestones with Name Change to MetaVia - Reflecting the Company's Focus on Cardiometabolic DiseasesNew Nasdaq Ticker Symbol will be MTVA CAMBRIDGE, Mass., Nov. 18, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced a strategic realignment, ahead of important clinical milestones, with a corporate name change to "MetaVia Inc.," which will be effective on November 29, 2024 (the "Effective Date"). In parallel, the Company's common stock will begin trading on the Nasdaq Stock Market under the new ticker symbol, "MTVA," which is expected to be operative as of the Effective Date. As part of its corporate name change, the company will also launch a new website, metaviatx.com, a
- 13D/GSEC Form SC 13G filed by NeuroBo Pharmaceuticals Inc.SC 13G - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)
- PRNeuroBo Pharmaceuticals to Participate in Investor Conferences in NovemberCAMBRIDGE, Mass., Nov. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced participation in the following investor conferences in November: November 14: Life Science Virtual Investor Forum. Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Thursday, November 14, at 1:00 pm ET. Management will also be available for one-on-one meetings during the event. Interested parties who would like to listen to the Company's presentation or request a meeting can do so after registering for the
- SECSEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.10-Q - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateReported Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity, Revealing Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics $21.7 Million in Cash at End of Third Quarter Expected to Fund the Company Into the Third Quarter of 2025 Top-Line Results from the Phase 2a Trial of DA-1241 for the Treatment of MASH Expected in December of 2024 Top-Line Data From the MAD Part 2 of the Phase 1 Trial of DA-1726 Expected in the First Quarter of 2025 Entered into a Joint Research Agreement, Together With Dong-A ST and ImmunoForge to Develop a Long-Acting Once-Monthly Formulation of DA-1726 CAMBRIDGE, Mass., Nov. 7, 2024 /PRN
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals to Participate in Investor Conferences in OctoberCAMBRIDGE, Mass., Oct. 1, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that management will participate in the following investor conferences in October: October 7: H.C. Wainwright 8th Annual MASH Virtual Conference. Hyung Heon Kim, President and Chief Executive Officer, will present a company overview on Monday, October 7, at 11:00 am ET.Management will also be available for one-on-one meetings during the event. Individuals who would like to listen to the Company's presentation or request a meeting can do so after registering for the conference at https://hcwevents.
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals Announces Positive Top-Line Data From the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityData Revealed Favorable Safety, Tolerability and Dose-Linear Pharmacokinetics (PK) Top-Line Data Readout from the MAD Part 2 Expected in the First Quarter of 2025 Planned Phase 1 Part 3 Will Evaluate Early Proof of Concept CAMBRIDGE, Mass., Sept. 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced positive top-line safety, tolerability, and dose-linear pharmacokinetics (PK) data from the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R)
- INSIDERLarge owner Dong-A St Co., Ltd sold $1,526 worth of shares (407 units at $3.75), decreasing direct ownership by 0.01% to 5,347,792 units (SEC Form 4)4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)
- 13D/GAmendment: SEC Form SC 13D/A filed by NeuroBo Pharmaceuticals Inc.SC 13D/A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Subject)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceCAMBRIDGE, Mass., Sept. 3, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that Hyung Heon Kim, President and Chief Executive Officer and Marshall H. Woodworth, Chief Financial Officer, will present a company overview on Tuesday, September 10, at 1:30 pm ET, during the H.C. Wainwright 26th Annual Global Investment Conference taking place September 9-11, 2024, in New York. Management will also be available for one-on-one meetings during the event. Institutional investors who would like to listen to the Company's presentation or request a meeting can do so after registeri
- SECSEC Form DEF 14A filed by NeuroBo Pharmaceuticals Inc.DEF 14A - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- SECSEC Form 10-Q filed by NeuroBo Pharmaceuticals Inc.10-Q - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateSuccessfully Completed a Financing of up to $70 Million, With $20 Million Upfront and an Additional $50 Million of Aggregate Gross Proceeds Upon the Exercise in Full of Clinical Milestone-Based Warrants $27.9 Million in Cash at End of Second Quarter is Expected to Fund the Company Though Multiple Value-Creating Milestones, Into the Second Quarter of 2025. Assuming Positive Results From the DA-1726 Phase 1 MAD Study, the Company Anticipates That the Series A Warrants From the June Financing Could be Exercised in the First Half of 2025, Resulting in Gross Proceeds of $20 Million In Pre-Clinical Models, DA-1726 Demonstrated Superiority in Weight Loss, Retention of Lean Body Mass and Lipid-Lowe
- INSIDERCEO & President Kim Hyung Heon covered exercise/tax liability with 11,467 shares, decreasing direct ownership by 15% to 66,666 units (SEC Form 4)4 - NeuroBo Pharmaceuticals, Inc. (0001638287) (Issuer)
- SECNeuroBo Pharmaceuticals Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - NeuroBo Pharmaceuticals, Inc. (0001638287) (Filer)
- PRNeuroBo Pharmaceuticals Completes Enrollment of the SAD Part 1 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of ObesityNo Significant Issues Encountered During the Single Ascending Dose (SAD) Study, Allowing for Previously Reported Accelerated Start to Multiple Ascending Dose (MAD) Part 2 Top Line Data Readout from SAD Part 1 Expected in the Third Quarter of 2024, and from the MAD Part 2 in the First Quarter of 2025 CAMBRIDGE, Mass., Aug. 13, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (NASDAQ:NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced the completion of enrollment of the single ascending dose (SAD) Part 1 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like pepti
NRBO FAQ
6 questionsWhat does NeuroBo Pharmaceuticals Inc. do?
NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo...Where does NRBO stock trade?
NeuroBo Pharmaceuticals Inc. (NRBO) is listed on NASDAQ.What sector and industry is NRBO in?
NeuroBo Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did NeuroBo Pharmaceuticals Inc. go public?
NeuroBo Pharmaceuticals Inc. (NRBO) completed its IPO in 2016.What companies are similar to NRBO?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare NRBO side-by-side with any of them on Quantisnow.How can I track NRBO on Quantisnow?
Quantisnow aggregates NeuroBo Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRBO to receive live email and push alerts on every new disclosure.